Judith Reinsdorf Net Worth

Judith Reinsdorf biography

Judith A. Reinsdorf serves as Independent Director of the Company. Ms. Reinsdorf previously served as Executive Vice President and General Counsel of Johnson Controls International, a global leader in building products and technology and integrated solutions from September 2016 to November 2017, following its merger with Tyco International, where she served as Executive Vice President and General Counsel from March 2007 until September 2016. Prior to Johnson Controls, Ms. Reinsdorf served as Vice President, General Counsel and Secretary of C. R. Bard, Inc., as Vice President and Corporate Secretary of Tyco, as Vice President and Associate General Counsel of Pharmacia Corporation, and as Assistant General Counsel and Chief Legal Counsel, Corporate, at Monsanto Company. Ms. Reinsdorf earned her bachelor’s degree from the University of Rochester and her J.D. from Cornell Law School.

What is the salary of Judith Reinsdorf?

As the Independent Director of Alexion Pharmaceuticals, the total compensation of Judith Reinsdorf at Alexion Pharmaceuticals is 470,013$. There are 12 executives at Alexion Pharmaceuticals getting paid more, with Ludwig Hantson having the highest compensation of 18,948,000$.

How old is Judith Reinsdorf?

Judith Reinsdorf is 56, she's been the Independent Director of Alexion Pharmaceuticals since 2018. There are 11 older and 7 younger executives at Alexion Pharmaceuticals. The oldest executive at Alexion Pharmaceuticals Inc. is John Mollen, 69, who is the Independent Director.

What's Judith Reinsdorf's mailing address?

Judith's mailing address filed with the SEC is C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, 94158.

Insiders trading at Alexion Pharmaceuticals

Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over 451,742,532$ worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth 277,855,180$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、Leonard Bell、Paul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of 3,460,578$. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth 2,816,685$.

What does Alexion Pharmaceuticals do?

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

Alexion Pharmaceuticals executives and stock owners

Alexion Pharmaceuticals executives and other stock owners filed with the SEC include:

• Ludwig Hantson,
  Chief Executive Officer, Director
• John Orloff,
  Executive Vice President, Head of Research and Development
• Brian Goff,
  Executive Vice President, Chief Commercial and Global Operations Officer
• Aradhana Sarin,
  Executive Vice President, Chief Financial Officer
• Dr. John J. Orloff,
  Exec. VP and Head of R&D
• Brian M. Goff,
  Exec. VP and Chief Commercial & Global Operations Officer
• Dr. Aradhana Sarin M.D.,
  Exec. VP & CFO
• Ellen V. Chiniara J.D., Esq.,
  Exec. VP, Chief Legal Officer & Corp. Sec.
• Christopher Coughlin,
  Independent Director
• David Brennan,
  Independent Chairman of the Board
• John Mollen,
  Independent Director
• Felix Baker,
  Independent Director
• Judith Reinsdorf,
  Independent Director
• Deborah Dunsire,
  Independent Director
• Andreas Rummelt,
  Independent Director
• Francois Nader,
  Independent Director
• Paul Friedman,
  Independent Director
• Uzair Qadeer,
  Chief Diversity Officer
• Becky Lillie,
  Interim Chief Human Experience Officer
• Tanisha Carino,
  Executive Vice President, Chief Corporate Affairs Officer
• Ellen Chiniara,
  Executive Vice President, Chief Legal Officer. Corporate Secretary
• Indrani Franchini,
  Executive Vice President, Chief Compliance Officer
• Megan Goulart,
  Sr. Director of Corp. Communications
• Christopher J. Stevo CFA,
  Head of Investor Relations
• Daniel A. Bazarko CPA,
  Chief Accounting Officer & Sr. VP
• Alvin S Parven,
  Director
• Julie O'neill,
  EVP. Global Operations
• Anne Marie Law,
  EVP, Chief Experience Officer
• Edward Miller,
  SVP, Chief Compliance Officer
• Ann M Veneman,
  Director
• M Michele Burns,
  Director
• David J Anderson,
  EVP, Chief Financial Officer
• Clare Carmichael,
  SVP, Chief HR Officer
• Carsten Thiel,
  SVP, EMEA & Asia Pacific
• Leonard Bell,
  Chief Executive Officer
• Heidi L Wagner,
  SVP, Global Government Affairs
• R Douglas Norby,
  Director
• Martin Mackay,
  EVP & Global Head of R&D
• John B Moriarty,
  SVP & General Counsel
• Paul J Clancy,
  EVP, Chief Financial Officer
• Daniel Bazarko,
  SVP, Controller, CAO
• Bros. Advisors Lp667, L.P.B...,
  
• Felixbaker Julian Baker Bro...,
  
• Max Link,
  Director
• Patrice Coissac,
  GM/President-ALXN Europe SAS
• William R Keller,
  Director
• Larry Mathis,
  Director
• David Hallal,
  Sr. VP Comm. Ops, Americas
• Stephen P Squinto,
  Executive VP
• Dominique Monnet,
  SVP, Chief Marketing Officer
• Thomas I H Dubin,
  Vice Pres. & General Counsel
• Frank J Wright,
  SVP, President Alxn Pharm Intl
• Vikas Sinha,
  SVP & Chief Financial Officer
• Saqib Islam,
  SVP, Chief Strat & Port. Off.
• Joseph A Madri,
  Director
• David W Keiser,
  President, Chief Operating Off
• Nancy Motola,
  VP Regulatory & Quality
• Katherine S Bowdish,
  Senior Vice President
• Barry P Luke,
  Vice Pres., Finance & Admin.
• Christopher F Mojcik,
  VP Clinical Development
• Scott A Rollins,
  Senior Vice President
• Carsten Boess,
  Vice President & CFO
• Jerry T Jackson,
  Director
• Ruedi E Waeger,
  Director